drugset / Trial / NCT02844881
Study of Apatinib and MASCT in Patients With Advanced Solid Tumors
Phase 1/2
Unknown
60 enrolled
The First People's Hospital of Lianyungang
Hengrui Yuanzheng Bio-Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is aimed to evaluate the efficacy and safety of Apatinib and MASCT in patients with advanced solid tumors.
Timeline
- Start
- 2016-07
- Primary completion
- 2018-07
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MASCT | Cell therapy | — | Intravenous |
| Subject | Rivoceranib | Small molecule | 850 mg | Oral |